Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling.
The DOI matches its Crossref record; 173 of the 174 references it cites were found in a registry or an index.
Abstract
Many studies have shown the central importance of the co-receptors CD28, inducible costimulatory molecule (ICOS) and cytotoxic T lymphocyte antigen 4 (CTLA4) in the regulation of many aspects of T-cell function. CD28 and ICOS have both overlapping and distinct functions in the positive regulation of T-cell responses, whereas CTLA4 negatively regulates the response. The signalling pathways that underlie the function of each of the co-receptors indicate their shared and unique properties and provide compelling hints of functions that are as yet uncovered. Here, we outline the shared and distinct signalling events that are associated with each of the co-receptors and provide unifying concepts that are related to signalling functions of these co-receptors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In mouse and human T cells the dimeric transmembrane glycoprotein CD28 represents the most important co-stimulatory molecule.”
From Signaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic Antibodies (2008) · cites this paper as [4]
In the citing paper
“Under physiological conditions CD28-derived signals alone are not capable of inducing T cell activation, whereas simultaneous engagement of the TCR and CD28 (e.g. by its natural ligands CD80 and CD86 which are expressed on mature antigen presenting cells) leads to activation of resting T lymphocytes (reviewed in [3], [4]).”
From Signaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic Antibodies (2008) · cites this paper as [4]
In the citing paper
“Under physiological conditions CD28-derived signals alone are not capable of inducing T cell activation, whereas simultaneous engagement of the TCR and CD28 (e.g. by its natural ligands CD80 and CD86 which are expressed on mature antigen presenting cells) leads to activation of resting T lymphocytes (reviewed in [3], [4]).”
From Signaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic Antibodies (2008) · cites this paper as [4]
Citations
Cites
Lipid rafts and signal transduction
Simons, K., & Toomre, D. (2000) · Nature Reviews Molecular Cell Biology · doi:10.1038/35036052 · Cited by 5,371
Phosphorylation meets ubiquitination: the control of NF-κB activity
Karin, M., & Ben-Neriah, Y. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.621 · Cited by 4,766
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914 · cited 1×
“CTLA4-deficient mice develop massive lymphoadenopathy, autoimmunity and early deat”
BackgroundLymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766 · cited 1×
“CTLA4-deficient mice develop massive lymphoadenopathy, autoimmunity and early deat”
BackgroundSH2 domains recognize specific phosphopeptide sequences
Zhou, S. (1993) · Cell · doi:10.1016/0092-8674(93)90404-e · Cited by 2,631
TRANSCRIPTION FACTORS OF THE NFAT FAMILY:Regulation and Function
Rao, A., Luo, C., & Hogan, P. G. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.707 · Cited by 2,603
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222 · cited 1×
“Co-ligation of CTLA4 with TCR, or with TCR and CD28 or TCR and ICOS inhibits proliferatio”
Signal transduction by lymphocyte antigen receptors
Weiss, A., & Littman, D. R. (1994) · Cell · doi:10.1016/0092-8674(94)90334-4 · Cited by 2,089
Three-dimensional segregation of supramolecular activation clusters in T cells
Monks, C. R. F., Freiberg, B. A., Kupfer, H., Sciaky, N., & Kupfer, A. (1998) · Nature · doi:10.1038/25764 · Cited by 1,968
Janssens, V., & Goris, J. (2001) · Biochemical Journal · doi:10.1042/0264-6021:3530417 · Cited by 1,902
Research works printed but not linked: 7
- Marinari, B. et al. Vav cooperates with CD28 to induce NF-κB activation via a pathway involving Rac-1 and mitogen-activated kinase kinase 1. Eur. J. Immunol. 32, 447–456 (2002). This study shows that dominant-negative forms of VAV can effectively block the induction of nuclear factor-κB (NF-κB) activation through a pathway that involves RAC1. · DOI · Paper page
- Ghaffari-Tabrizi, N. et al. Protein kinase C-θ, a selective upstream regulator of JNK/SAPK and IL-2 promoter activation in Jurkat T cells. Eur. J. Immunol. 29, 132–142 (1999). · DOI · Paper page
- Tuosto, L. et al. Mitogen-activated kinase kinase kinase 1 regulates T cell receptor- and CD28-mediated signaling events which lead to NF-κB activation. Eur. J. Immunol. 30, 2445–2454 (2000). · DOI · Paper page
- Dimitratos, S. D., Woods, D. F., Stathakis, D. G. & Bryant, P. J. Signaling pathways are focused at specialized regions of the plasma membrane by scaffolding proteins of the MAGUK family. Bioessays 21, 912–921 (1999). · DOI · Paper page
- Schneider, H., da Rocha Dias, S., Hu, H. & Rudd, C. E. A regulatory role for cytoplasmic YVKM motif in CTLA-4 inhibition of TCR signaling. Eur. J. Immunol. 31, 2042–2050 (2001). · DOI · Paper page
- Nakaseko, C. et al. Cytotoxic lymphocyte antigen 4 (CTLA-4) engagement delivers an inhibitory signal through the membrane-proximal region in the absence of the tyrosine motif in the cytoplasmic tail. J. Exp. Med. 190, 765–774 (1999). · DOI · Paper page
- Tuosto, L. & Acuto, O. CD28 affects the earliest signaling events generated by TCR engagement. Eur. J. Immunol. 28, 2131–2142 (1998). · doi:10.1002/(sici)1521-4141(199807)28:07<2131::aid-immu2131>3.0.co;2-q
Cited by
Items 101–200 of 393
Parry, R. V., & Ward, S. G. (2005) · Wiley eBooks · doi:10.1038/npg.els.0001184 · Cited by 74
Pedros, C., Zhang, Y., Hu, J. K., Choi, Y. S., Canonigo-Balancio, A. J., Yates, J. R., Altman, A., Crotty, S., & Kong, K. (2016) · Nature Immunology · doi:10.1038/ni.3463 · Cited by 87
Massarelli, E., Lam, V. K. L., Parra, E. R., Rodriguez‐Canales, J., Behrens, C., Diao, L., Wang, J., Blando, J. M., Byers, L. A., Yanamandra, N., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0827-2 · Cited by 78
“In fact, ICOS is a member of the CD28/CTLA-4 family; it is expressed on activated T cells and its ligand, B7H/B7RP-1, is expressed on B cells and in non-immune tissues after injection of lipopolysaccharide into animals [45, 46].”
BackgroundControlling NF-κB activation in T cells by costimulatory receptors
Schmitz, M. L., & Krappmann, D. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401845 · Cited by 82
“Different coreceptors can be engaged by overlapping ligands, as in the case for CD28 and CTLA4, which are competing for association of B7-1 (CD80) or B7-2 (CD86) on APCs.8 Other coreceptors are triggered by distinct ligands, for example, B7H for ICOS, PD-1L for PD-1 and K12 for CD7.”
BackgroundCD46 processing: A means of expression
Choileáin, S. N., & Astier, A. (2011) · Immunobiology · doi:10.1016/j.imbio.2011.06.003 · Cited by 72
The role of ICOS in the development of CD4 T cell help and the reactivation of memory T cells
Mahajan, S., Cervera, A. M., MacLeod, M. K. L., Fillatreau, S., Perona‐Wright, G., Meek, S. E., Smith, A., MacDonald, A. S., & Gray, D. (2007) · European Journal of Immunology · doi:10.1002/eji.200636661 · Cited by 70
Vessillier, S., Eastwood, D., Fox, B. J., Sathish, J. G., Sethu, S., Dougall, T., Thorpe, S. J., Thorpe, R., & Stebbings, R. (2015) · Journal of Immunological Methods · doi:10.1016/j.jim.2015.04.020 · Cited by 76
“Some IL-2 signaling may have occurred via the intermediate-affinity IL-2R (βγc chain complex) present on resting T cells and CD56bright NK cells, since daclizumab only blocks the high-affinity IL-2R (αβγc chain complex) present on activated T cells (Sheridan et al., 2011; Liao et al., 2013).”
BackgroundPI3Ks in Lymphocyte Signaling and Development
Okkenhaug, K., & Fruman, D. A. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_45 · Cited by 70
T cell exhaustion and Interleukin 2 downregulation
Balkhi, M. Y., Ma, Q., Ahmad, S., & Junghans, R. P. (2014) · Cytokine · doi:10.1016/j.cyto.2014.11.024 · Cited by 76
Immune Checkpoint Therapy for Non-Small-Cell Lung Cancer: An Update
Xia, B., & Herbst, R. S. (2016) · Immunotherapy · doi:10.2217/imt.15.123 · Cited by 67
Diverse Mechanisms Regulate the Surface Expression of Immunotherapeutic Target CTLA-4
Schneider, H., & Rudd, C. E. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00619 · Cited by 74
“Like CD28 and ICOS, CTLA-4 possesses a small cytoplasmic tail containing, apart from its Cterminal YFIP motif, a YxxM consensus motif common of all three co-receptors (64) (Figure 1).”
BackgroundSelf-citationEvidence for unique association signals in SLE at the CD28–CTLA4–ICOS locus in a family-based study
Graham, D. S. C., Wong, A., McHugh, N. J., Whittaker, J. C., & Vyse, T. J. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl395 · Cited by 68
“cells (APCs), including dendritic cells, B cells and monocytes (11).”
BackgroundWatanabe, R., Harada, Y., Takeda, K., Takahashi, J., Ohnuki, K., Ogawa, S., Ohgai, D., Kaibara, N., Koiwai, O., Tanabe, K., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.2.1085 · Cited by 62
“The best characterized costimulatory pair is CD28 and its ligands, CD80 (B7-1) and CD86 (B7-2) (1, 2).”
BackgroundMechanisms of CTLA-4-Ig in Tolerance Induction
Alegre, M., & Fallarino, F. (2005) · Current Pharmaceutical Design · doi:10.2174/138161206775193046 · Cited by 67
de Souza, A. J., Oak, J. S., Jordanhazy, R., DeKruyff, R. H., Fruman, D. A., & Kane, L. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.10.6518 · Cited by 72
“have been frequently implicated in costimulatory signaling (13).”
BackgroundPorciello, N., & Tuosto, L. (2016) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2016.02.004 · Cited by 61
Chen, H., Fu, T., Suh, W., Tsavachidou, D., Wen, S., Gao, J., Tang, D. N., He, Q., Sun, J., & Sharma, P. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0155 · Cited by 61
“In addition, ICOS has been shown to play a role in Th2 immune responses (7) and it will be necessary to evaluate whether, under specific conditions, ICOS regulates the expression of GATA-3.”
BackgroundInfluentialTaylor, A., & Rudd, C. E. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01653 · Cited by 61
Self-citationAnti–PD-1 Antibody Treatment Promotes Clearance of Persistent Cryptococcal Lung Infection in Mice
Roussey, J. A., Viglianti, S. P., Teitz‐Tennenbaum, S., Olszewski, M. A., & Osterholzer, J. J. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700840 · Cited by 64
“We examined the expression of ICOS, known to be important in secondary stimulation of activated T cells (45), and OX40, which promotes memory T cell responses and has previously been shown to enhance fungal clearance in C.”
Álvarez‐Errico, D., Sayós, J., & López‐Botet, M. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.2.808 · Cited by 57
“To our knowledge, CTLA-4 constitutes the best example of a receptor involved in negative regulation of T cell functions capable of recruiting class 1A PI3K (36, 37), a property shared with its homologous CD28 and ICOS costimulatory molecules.”
BackgroundMoon, J. J., Rubio, E. D., Martino, A., Krumm, A., & Nelson, B. H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m308998200 · Cited by 64
Lebsack, T. W., Fa, V., Woods, C. C., Gruener, R., Manziello, A. M., Pecaut, M. J., Gridley, D. S., Stodieck, L. S., Ferguson, V. L., & DeLuca, D. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22547 · Cited by 55
“CTLA-4, which is expressed mainly on CD4þ T cells and has well documented T cell inhibitory functions and plays a key role in regulating and controlling T cell proliferation and activation [Fraser et al., 1999; Rudd and Schneider, 2003; Mao et al., 2004].”
BackgroundChialda, L., Zhang, M., Brune, K., & Pahl, A. M. (2005) · Respiratory Research · doi:10.1186/1465-9921-6-36 · Cited by 54
“PD-1 is an inhibitory CD28-like receptor, with two B7-like ligands (PD-L1 and PD-L2) [12,13].”
BackgroundEmerging Co-signaling Networks in T Cell Immune Regulation
Jung, K., & Choi, I. (2013) · Immune Network · doi:10.4110/in.2013.13.5.184 · Cited by 59
“ment of protein kinase Cθ (PKCθ) and RAS guanyl nucleotide-releasing protein (RASGRP) to the immunological synapse and its subsequent activation (5-7).”
BackgroundSignals that drive T follicular helper cell formation
Webb, L. M. C., & Linterman, M. A. (2017) · Immunology · doi:10.1111/imm.12778 · Cited by 61
How the Discovery of the CD4/CD8-p56lck Complexes Changed Immunology and Immunotherapy
Rudd, C. E. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.626095 · Cited by 62
Self-citationImmune checkpoint inhibitors for the treatment of melanoma
Sabbatino, F., Liguori, L., Pepe, S., & Ferrone, S. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2038132 · Cited by 61
“tion of T cells and as a result for the development of a host’s immune response [6,7].”
BackgroundCBLBvariants in type 1 diabetes and their genetic interaction withCTLA4
Bergholdt, R., Taxvig, C., Eising, S., Nerup, J., & Pociot, F. (2005) · Journal of Leukocyte Biology · doi:10.1189/jlb.0904524 · Cited by 54
“CTLA-4 may counter-regulate the CD28 T cell antigen receptor activation of T cells and has an even stronger affinity for binding to ligands on the antigen-presenting cells, although mechanisms are not fully understood [18].”
BackgroundImmunopathogenesis of Idiopathic Nephrotic Syndrome
Zhang, S. Y., Audard, V., Fan, Q., Pawlak, A., Lang, P., & Sahali, D. (2011) · Contributions to nephrology · doi:10.1159/000313947 · Cited by 56
Molecular control of Tfh‐cell differentiation by Roquin family proteins
Heissmeyer, V., & Vogel, K. U. (2013) · Immunological Reviews · doi:10.1111/imr.12056 · Cited by 57
“Ox40 and Icos may therefore play a critical role in the development of Tfh cells, especially as both costimulatory receptors overlap in their downstream signaling (22).”
BackgroundTIGIT, A Novel Therapeutic Target for Tumor Immunotherapy
Liu, X., Hou, M., & Liu, Y. (2016) · Immunological Investigations · doi:10.1080/08820139.2016.1237524 · Cited by 47
“The upregulated CLTA4 can outcompete CD28 for CD80/86 binding and attenuates T-cell responses through IL-2 deprivation, blockade of cell cycle progression, and tolerogenic DC induction (Rudd & Schneider, 2003; Sharpe & Freeman, 2002).”
BackgroundBTLA and HVEM Cross Talk Regulates Inhibition and Costimulation
Gavrieli, M., Šedý, J. R., Nelson, C. A., & MURPHY, K. M. M. (2006) · Advances in immunology · doi:10.1016/s0065-2776(06)92004-5 · Cited by 50
Transcriptional basis of lymphocyte tolerance
Borde, M., Barrington, R. A., Heissmeyer, V., Carroll, M. C., & Rao, A. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00370.x · Cited by 50
Tan, A. H., Wong, S. C., & Lam, K. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604081200 · Cited by 48
Elias, R. M., Sardinha, L. R., Bortoluci, K. R., Zago, C. A., da Silva, A. P. F., Álvarez, J. M., & Lima, M. R. D. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.2.790 · Cited by 51
“by ICOS/ICOS ligand interaction (26), but it could be important to”
BackgroundGrimbacher, B., Warnatz, K., & Peter, H. (2003) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/00130832-200312000-00001 · Cited by 47
Genotype and Phenotype Predictors of Relapse of Graves’ Disease after Antithyroid Drug Withdrawal
Wang, P., Chen, I., Juo, S. H., Hsi, E., Liu, R., & Hsieh, C. (2012) · European Thyroid Journal · doi:10.1159/000342621 · Cited by 47
Sanchez-Lockhart, M., Graf, B., & Miller, J. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.11.7639 · Cited by 46
“However, CD28 costimulation does not appear to generate a localized concentration of phosphatidylinositol-(3,4,5)triphosphate (the product of PI3K) within the cSMAC (C.”
BackgroundWan, S., Ni, L., Zhao, X., Liu, X., Xu, W., Jin, W., Wang, X., & Dong, C. (2021) · Immunity · doi:10.1016/j.immuni.2021.09.018 · Cited by 46
Differential Control of CD28-Regulated In Vivo Immunity by the E3 Ligase Cbl-b
Krawczyk, C. M., Jones, R. G., Atfield, A., Bachmaier, K., Arya, S., Odermatt, B., Ohashi, P. S., & Penninger, J. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.3.1472 · Cited by 49
Taner, S. B., Önfelt, B., Pirinen, N. J., McCann, F. E., Magee, A. I., & Davis, D. M. (2004) · Traffic · doi:10.1111/j.1600-0854.2004.00214.x · Cited by 48
“TCR signaling events phosphorylate CTLA-4 to prevent binding to the AP-2 complex and subsequent endocytosis ((7,8) and references therein).”
BackgroundLu, Y., Schneider, H., & Rudd, C. E. (2012) · Blood · doi:10.1182/blood-2012-04-421420 · Cited by 47
Self-citationGeneral aspects of the genetics of SLE
Rhodes, B., & Vyse, T. J. (2007) · Autoimmunity · doi:10.1080/08916930701510657 · Cited by 47
“2, down-regulates the activated Tcells [92].”
New approach reveals CD28 and IFNG gene interaction in the susceptibility to cervical cancer
Guzman, V. B., Yambartsev, A., Gonçalves-Primo, A., da Silva, I. D. C. G., Carvalho, C. R. N., Ribalta, J. C. L., Goulart, L. R., Shulzhenko, N., Gerbase‐DeLima, M., & Morgun, A. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn077 · Cited by 43
“It is also known that regulation of the NFkB transcription family in T cells involves signaling through CD28 (37).”
BackgroundJones, R. G., Saibil, S. D., Pun, J. M., Elford, A. R., Bonnard, M., Pellegrini, M., Arya, S., Parsons, M. E., Krawczyk, C. M., Gerondakis, S., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.6.3790 · Cited by 43
“Lipid second messengers generated downstream of the TCR and the costimulatory molecule CD28 play an important role in regulating T cell viability (9).”
BackgroundWood, J. E., Schneider, H., & Rudd, C. E. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604878200 · Cited by 42
Self-citationHuang, Y., Wang, Z., Zheng, Q., Tang, J., Cai, J. X., Lu, Y., & Jian, J. (2017) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2017.10.008 · Cited by 43
Evidence for a Role for Notch Signaling in the Cytokine-Dependent Survival of Activated T Cells
Bheeshmachar, G., Purushotaman, D., Sade, H., Gunasekharan, V. K., Rangarajan, A., & Sarin, A. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.8.5041 · Cited by 44
“ecule for T cell survival and the development of effectors (28) and FIGURE 8.”
BackgroundCD300 Heterocomplexes, a New and Family-restricted Mechanism for Myeloid Cell Signaling Regulation
Martínez‐Barriocanal, Á., Comas-Casellas, E., Schwartz, S., Martín, M., & Sayós, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.140889 · Cited by 47
Jang, B., & Kim, I. A. (2018) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2018.05.003 · Cited by 44
Sellebjerg, F. T., Krakauer, M., Khademi, M., Olsson, T. P., & Sørensen, P. S. (2012) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2012.04654.x · Cited by 42
Schneider, H., & Rudd, C. E. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.02.068 · Cited by 39
“The co-receptor CD28 binds to several intracellular proteins including PI3 kinase, Grb-2, Gads and ITK.”
BackgroundInfluentialSelf-citationThe identification and functional analysis of CD8+PD-1+CD161+ T cells in hepatocellular carcinoma
Li, Z., Zheng, B. J., Qiu, X., Wu, R. T., Wu, T., Yang, S., Zhu, Y., Wu, X., Wang, S., Gu, Z., et al. (2020) · npj Precision Oncology · doi:10.1038/s41698-020-00133-4 · Cited by 46
Immune Checkpoint Molecules: A Review on Pathways and Immunotherapy Implications
Rezazadeh‐Gavgani, E., Majidazar, R., Lotfinejad, P., Kazemi, T., & Shamekh, A. (2025) · Immunity Inflammation and Disease · doi:10.1002/iid3.70196 · Cited by 55
“Thus, the detectable amount of CTLA ‐ 4 on the cell surface is primarily low, and higher ligation affinity is focused predominantly on the intracellular sites [48, 50, 51].”
Yang, M., Sun, T., Zhou, Y., Wang, L., Liu, L., Zhang, X., Tang, X., Zhou, M., Kuang, P., Tan, W., et al. (2012) · Cancer · doi:10.1002/cncr.27455 · Cited by 39
“Cytotoxic T lymphocyte–associated Protein 4 (CTLA-4, also known as CD152) is a member of the immunoglobulin superfamily and is expressed on activated T cells.(1,2) Similar to CD28 (another T cell costimulatory molecule), CTLA-4 binds to B7.”
BackgroundCTLA‐4 co‐receptor impacts on the function of Treg and CD8+ T‐cell subsets
Rudd, C. E. (2009) · European Journal of Immunology · doi:10.1002/eji.200939261 · Cited by 47
Self-citationGenome‐wide meta‐analysis identifies susceptibility loci for autoimmune hepatitis type 1
Li, Y., Sun, Y., Liu, Y., Wang, B., Li, J., Wang, H., Zhang, H., Wang, X., Han, X., Lin, Q., et al. (2022) · Hepatology · doi:10.1002/hep.32417 · Cited by 37
“[36] Having a higher affinity to activating ligands, CTLA4 dampens T- cell responses and inhibits excessive expansion of activated T cells.[37,38] Expressed on activated T cells, ICOS can deliver additional costimulatory signals to further enhance T- cell activation and differentiation, including T helper 1 and 17 and…”
Emergence of the CD226 Axis in Cancer Immunotherapy
Conner, M., Hance, K. W., Yadavilli, S., Smothers, J. F., & Waight, J. D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.914406 · Cited by 48
Regulation of PD-L1 Trafficking from Synthesis to Degradation
Lemma, E. Y., Letian, A., Altorki, N. K., & McGraw, T. E. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0953 · Cited by 47
Sagi, Y., Landrigan, A., Levy, R., & Levy, S. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121307109 · Cited by 44
“However, additional members of the CD28 family, such as ICOS and several members of the TNF family, such as CD27 and CD137 (4-1BB) are well known T-cell costimulatory molecules (13, 14).”
BackgroundA Comparative Perspective on Wnt/β-Catenin Signalling in Cell Fate Determination
Garcin, C. L., & Habib, S. J. (2017) · Results and problems in cell differentiation · doi:10.1007/978-3-319-53150-2_15 · Cited by 43
Expanding Clinical Phenotype and Novel Insights into the Pathogenesis of ICOS Deficiency
Abolhassani, H., El-Sherbiny, Y. M., Arumugakani, G., Carter, C. R. D., Richards, S. J., Lawless, D., Wood, P. M. D., Buckland, M. S., Arani, M. H., Aghamohammadi, A., et al. (2019) · Journal of Clinical Immunology · doi:10.1007/s10875-019-00735-z · Cited by 36
Jiang, L., Nie, S., Zhou, H., Huang, D., & Xie, M. (2014) · International Immunopharmacology · doi:10.1016/j.intimp.2014.06.027 · Cited by 36
Sun, M., Lee, S., Karray, S., Lévi‐Strauss, M., Ames, K. T., & Fink, P. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.9.5639 · Cited by 35
“, NF- B) essential for cell survival but not for cell proliferation or IL-2 production (4, 21).”
BackgroundSanchez-Lockhart, M., & Miller, J. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.8.4778 · Cited by 35
“Despite the well-recognized functional importance of CD28, the biochemical signaling pathways induced downstream of CD28 are still not completely understood (1, 4).”
BackgroundMadrenas, J., Chau, L. A., Teft, W. A., Wu, P. W., Jussif, J. M., Kasaian, M. T., Carreno, B. M., & Ling, V. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.10.5948 · Cited by 41
“The other mechanism involves negative signaling through its cytoplasmic tail by a still uncharacterized mechanism (4, 5).”
BackgroundICOS protects against mortality from acute lung injury through activation of IL-5+ ILC2s
Hrusch, C. L., Manns, S. T., Bryazka, D., Casaos, J., Bonham, C. A., Jaffery, M., Blaine, K. M., Mills, K. A. M., Verhoef, P. A., Adegunsoye, A., et al. (2017) · Mucosal Immunology · doi:10.1038/mi.2017.42 · Cited by 36
APC, T Cells, and the Immune Synapse
Reichardt, P., Dornbach, B., & Gunzer, M. (2009) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-03858-7_12 · Cited by 43
“While CD28 is a molecule providing positive signals, CTLA-4 is a master negative switch of T cell activation ( Rudd and Schneider 2003 ).”
BackgroundMathematical Models and Immune Cell Biology
Molina-París, C., & Lythe, G. (2011) · Springer eBooks · doi:10.1007/978-1-4419-7725-0 · Cited by 43
Cross-talk between intraepithelial γδ T cells and epithelial cells
Witherden, D. A., & Havran, W. L. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.0213101 · Cited by 35
“receptor, ICOS [41].”
Association of the CD28/CTLA4/ICOS polymorphisms with susceptibility to rheumatoid arthritis
Kim, Y. O., Kim, H. J., Kim, S. K., Chung, J., & Hong, S. (2010) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2010.074 · Cited by 32
“The B7-1 (CD80) and B7-2 (CD86) ligands that are expressed on antigen-presenting cells are shared by the positive and negative receptors (CD28 and CTLA4, respectively) (4).”
BackgroundChimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies
Biagi, E., Marin, V., Attianese, G. M. P. G., Dander, E., D’Amico, G., & Biondi, A. (2007) · Haematologica · doi:10.3324/haematol.10873 · Cited by 33
Liu, Y., Zhang, Z., Wang, S., Fu, S., Cheng, X., Chen, R., & Sun, T. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108900 · Cited by 35
Emerging antibody-based therapeutic strategies for bladder cancer: A systematic review
Azevedo, R., Ferreira, J. A., Peixoto, A., Neves, M., Sousa, N., Lima, Á., & Santos, L. L. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.07.002 · Cited by 36
Ohnuma, K., Uchiyama, M., Hatano, R., Takasawa, W., Endo, Y., Dang, N. H., & Morimoto, C. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.06.027 · Cited by 32
Immunoregulatory molecules in patients with gestational diabetes mellitus
Pendeloski, K. P. T., Mattar, R., Torloni, M. R., Gomes, C. P., Alexandre, S. M., & Daher, S. (2015) · Endocrine · doi:10.1007/s12020-015-0567-0 · Cited by 32
“Despite some studies which evaluated PD-1 in the decidua, its role in pregnancy is still unclear and there are no data on ICOS expression in pregnant women [4, 6, 26, 27].”
BackgroundInfluentialImmunotherapies: The Blockade of Inhibitory Signals
Wu, Y., Liang, J., Zhang, W., Tanaka, Y., & Sugiyama, H. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.5273 · Cited by 35
“Whereas the cytoplasmic tail of CTLA-4 contains a YVKM motif, a typical immunoreceptor tyrosine-based inhibitory motif (ITIM), the molecules and the mechanism involved in this negative signal pathway has not been fully elucidated [8].”
BackgroundWei, B., Dias, S. D. R., Wang, H., & Rudd, C. E. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.1.400 · Cited by 35
“As we previously described, CTLA-4 has a Tyr-Xaa-Xaa-Met motif that binds to the Src homology 2 domain of the p85 subunit of PI3K (3).”
BackgroundSelf-citationThe 3′ UTR of the human CTLA4 mRNA can regulate mRNA stability and translational efficiency
Malquori, L., Carsetti, L., & Ruberti, G. (2007) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2007.10.004 · Cited by 31
Two pathways of costimulation through CD28
Miller, J., Baker, C. M., Cook, K. D., Graf, B. A., Sánchez-Lockhart, M., Sharp, K., Wang, X., Yang, B. C., & Yoshida, T. (2009) · Immunologic Research · doi:10.1007/s12026-009-8097-6 · Cited by 40
“CD28 has been shown to have important functional consequences on T cell activation [3] [4] [5] [6] .”
BackgroundShao, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03055 · Cited by 29
“The key downstream target of CTLA-4 is Akt, which is also an upstream signal for ATM (29).”
BackgroundModulation of factor VIII‐specific memory B cells
Reipert, B. M., Allacher, P., Hausl, C., Pordes, A. G., Ahmad, R. U., LANG, I., Ilas, J., Windyga, J., Klukowska, A., Muchitsch, E. M., et al. (2010) · Haemophilia · doi:10.1111/j.1365-2516.2008.01962.x · Cited by 29
Barisani, D., Ceroni, S., Meneveri, R., Cesana, B. M., & Bardella, M. R. T. (2006) · Genetics in Medicine · doi:10.1097/01.gim.0000204464.87540.39 · Cited by 28
Immunological role and underlying mechanisms of B7‐H6 in tumorigenesis
Hu, Y., Zeng, T., Zheng, X. W., Hu, Q.-H., Li, Y., Tan, X., Yue, H., Wang, W., Tan, H., & Zou, J. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.12.030 · Cited by 28
Prevention of lethal acute GVHD with an agonistic CD28 antibody and rapamycin
Albert, M. H., Yu, X., Martin, P. J., & Anasetti, C. (2005) · Blood · doi:10.1182/blood-2004-08-3305 · Cited by 28
T-lymphocyte signalling in systemic lupus erythematosus: a lipid raft perspective
Jury, E. C., & Kabouridis, P. S. (2004) · Lupus · doi:10.1191/0961203304lu1045rr · Cited by 28
Coinhibitory T-Cell Signaling in Islet Allograft Rejection and Tolerance
Truong, W., Hancock, W. W., Anderson, C. C., Merani, S., & Shapiro, A. M. J. (2006) · Cell Transplantation · doi:10.3727/000000006783982160 · Cited by 30
Orvain, C., Cauvet, A., Prudent, A., Guignabert, C., Thuillet, R., Ottaviani, M., Tu, L., Duhalde, F., Nicco, C., Batteux, F., et al. (2022) · Arthritis Research & Therapy · doi:10.1186/s13075-021-02709-2 · Cited by 28
“CD28 and inducible T cell costimulator (ICOS) are closely related T cell costimulatory molecules within the immunoglobulin superfamily that bind, respectively, the ligands CD80 and CD86, and ICOS ligand (ICOSL), and play partially overlapping roles in immunity [7].”
BackgroundLu, Z., Condomines, M., Tarte, K., Nadal, L., Delteil, M. C., Rossi, J. F., Ferrand, C., & Klein, B. (2007) · Experimental Hematology · doi:10.1016/j.exphem.2006.11.002 · Cited by 25
“B7/CD28 T cell activation is downregulated by CTLA-4 [2,5].”
BackgroundInfluentialXu, L., Chen, Y., Xiong, L., Shen, Y., Zhou, Z., Wang, S., & Xu, X. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2512645 · Cited by 36
Two Strings in One Bow: PD-1 Negatively Regulates via Co-receptor CD28 on T Cells
Krueger, J., & Rudd, C. E. (2017) · Immunity · doi:10.1016/j.immuni.2017.04.003 · Cited by 26
“…tails, CD28, CTLA-4, and ICOS share a similar Tyr-xx-Met (i.e., YxxM) motif that binds to the lipid kinase phosphatidylinositol 3-kinase (PI-3K) and, in the case of CD28, also to the adaptor protein GRB-2 (GRB2 growth factor receptor-bound protein 2; Rudd and Schneider, 2003; Figure 1, bottom).”
BackgroundInfluentialSelf-citationTargeting Costimulatory Pathways for Tumor Immunotherapy
Ward, R. C., & Kaufman, H. L. (2007) · International Reviews of Immunology · doi:10.1080/08830180701365941 · Cited by 27
Host immunology and rational immunotherapy for carbapenem-resistant Klebsiella pneumoniae infection
Iwanaga, N., Sandquist, I., Wanek, A. G., McCombs, J. E., Song, K., & Kolls, J. K. (2020) · JCI Insight · doi:10.1172/jci.insight.135591 · Cited by 24
“ICOS is one of the CD28 family of costimulatory molecules and is highly expressed on the activated T cell (30, 31), especially type 2 helper T cells (32) and ILC2 (33), contributing to the isotype switch and germinal center formation (34).”
BackgroundDetailed bladder cancer immunoprofiling reveals new clues for immunotherapeutic strategies
Viveiros, N., Flores, B. C. T., Lobo, J., Martins‐Lima, C., Cantante, M., Lopes, P., Deantonio, C., Palu, C. C., Sainson, R. C. A., Henrique, R., et al. (2022) · Clinical & Translational Immunology · doi:10.1002/cti2.1402 · Cited by 24
“PD-1, ICOS is a costimulatory molecule that enhances T cells function.(15,16) Thus, ICOS endures both anti- and pro-tumor activities, depending on the T-cell subpopulation.”
BackgroundHatano, R., Ohnuma, K., Otsuka, H., Komiya, E., Taki, I., Iwata, S., Dang, N. H., Okumura, K., & Morimoto, C. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1402143 · Cited by 27
“inhibits the formation of lipid rafts (18).”
BackgroundJiménez‐Periáñez, A., Ojeda, G., Criado, G., Sánchez, A., Pini, E., Madrenas, J., Rojo, J. M., & Portolés, P. (2005) · Journal of Leukocyte Biology · doi:10.1189/jlb.1104642 · Cited by 24
Legány, N., Berta, L., Kovács, L., Balog, A., & Toldi, G. (2016) · Immunologic Research · doi:10.1007/s12026-016-8880-0 · Cited by 24
“Multiple mechanisms for CTLA-4mediated immunosuppression include competition for CD28 binding and induction of suppressive intracellular signaling pathways such as cytokine-dependent tryptophan catabolism and upregulation of IDO in B7-expressing APCs [9, 23].”
BackgroundMin, J. L., Meulenbelt, I., Kloppenburg, M., van Duijn, C. M., & Slagboom, P. E. (2007) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201829 · Cited by 24
TCR/CD3 mediated stop-signal is decoupled in T-cells from Ctla4 deficient mice
Downey, J., Smith, A. M., Schneider, H., Hogg, N., & Rudd, C. E. (2007) · Immunology Letters · doi:10.1016/j.imlet.2007.09.004 · Cited by 24
Self-citationAnti-CD40 mAb enhanced efficacy of anti-PD1 against osteosarcoma
Zhang, J., Li, Y., Yang, S. Y. C., Zhang, L., & Wang, W. (2019) · Journal of bone oncology · doi:10.1016/j.jbo.2019.100245 · Cited by 23
Metadata
- Authors
- Rudd, C. E., & Schneider, H.
- Affiliations
- Hammersmith Hospital (GB)
- Corresponding author
- Rudd, Christopher E.
- ORCID
- Rudd, Christopher E.
- Venue
- Nature Reviews Immunology
- Published
- 2003-07
- Volume
- 3
- Issue
- 7
- Pages
- 544-556
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W2001716606
- Cited by
- 392
- References
- 174
- Citations by year
- 2026: 10 · 2025: 15 · 2024: 12 · 2023: 9 · 2022: 17 · 2021: 15 · 2020: 16 · 2019: 14 · 2018: 13 · 2017: 15 · 2016: 16 · 2015: 13 · 2014: 9 · 2013: 19 · 2012: 13
- FWCI
- 2.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CD28, ICOS, CTLA-4, T cell activation, T cell costimulation, T cell tolerance, signaling pathways
- MeSH terms
- Abatacept, Amino Acid Sequence, Animals, Antigens, Differentiation, T-Lymphocyte, Humans, Molecular Sequence Data, Proto-Oncogene Proteins, T-Lymphocytes, Signal Transduction, NF-kappa B, Protein Serine-Threonine Kinases, CD28 Antigens, Immunoconjugates, Cell Cycle Proteins, Phosphatidylinositol 3-Kinases, Mitogen-Activated Protein Kinase Kinases, JNK Mitogen-Activated Protein Kinases, MAP Kinase Kinase 4, MAP Kinase Kinase Kinase 1, Proto-Oncogene Proteins c-akt, Proto-Oncogene Proteins c-vav, Inducible T-Cell Co-Stimulator Protein, 3-Phosphoinositide-Dependent Protein Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.